Sector News

Pfizer bags CMV vaccine with Redvax buy

January 5, 2015
Life sciences
Pfizer has acquired a controlling interest in Redvax, a spin-off from Switzerland’s Redbiotec, giving it access to a preclinical human cytomegalovirus vaccine candidate.
The transaction, the financial details for which have not been disclosed, includes intellectual property and a technology platform related to a second, undisclosed vaccine programme. CMV is a herpes virus and one out of every five children born with infection may experience hearing loss and severe neurologic disorders.
Pfizer noted that more children have disabilities due to congenital CMV than “other well-known infections and syndromes”, including Down syndrome, fetal alcohol syndrome, spina bifida and paediatric HIV/AIDS. It also cited the Institute of Medicine’s ranking of the development of a CMV vaccine as a highest priority; the estimated costs associated with the disease for the US healthcare system is at least $1.86 billion annually, more than $300,000 per child.
Kathrin Jansen, head of vaccine research and early development at Pfizer, said that with the acquisition of Redvax, “we will seek to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children.”
By Kevin Grogan
Source: Pharma Times

Related News

September 25, 2020

Novo Nordisk tees up phase 3 trial for once-weekly insulin

Life sciences

People with Type 2 diabetes are no strangers to needles, with some injecting bolus insulin after meals, others injecting basal insulin once or twice a day, and others still doing […]

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]